Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the presentation of results d...